Colorectal Cancer Clinical Trials

163 studies are recruiting for colorectal cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Researching the Effect of Exercise on Cancer

   Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA fo…

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Medical Center, Durate, California

   Locations

   9 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT04589468 on ClinicalTrials.gov

2. Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

   Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS with HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers.…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04847063 on ClinicalTrials.gov

3. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

   This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   5 in total

   Run by

   Immunome, Inc.

   See if you can join NCT07578571 on ClinicalTrials.gov

4. Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

   The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemt…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Genesis Cancer Center Hot Springs National Park, Hot Springs, Arkansas

   Locations

   5 in total

   Run by

   Genmab

   See if you can join NCT07775287 on ClinicalTrials.gov

5. This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

   This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing stan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Run by

   LTZ Therapeutics, Inc.

   See if you can join NCT07878988 on ClinicalTrials.gov

6. Evaluation for NCI Surgery Branch Clinical Research Protocols

   Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This stud…

   Stage

   Not phased

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00001823 on ClinicalTrials.gov

7. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSD, La Jolla, California

   Locations

   54 in total

   Run by

   Genmab

   See if you can join NCT03526835 on ClinicalTrials.gov

8. FITting Non-invasive Tests in Lynch Syndrome Surveillance

   The purpose of this clinical study is to evaluate the accuracy of the fecal immunochemical test (FIT) in comparison to colonoscopy in patients with Lynch Syndrome (LS) who are undergoing colonoscopy surveillance.

   Stage

   Not phased

   Ages

   20 to 80

   Site

   The University of Chicago Medical Center, Chicago, Illinois

   Locations

   3 in total

   Run by

   University of Chicago

   See if you can join NCT06898996 on ClinicalTrials.gov

9. LYL273 for Patients With Relapsed or Refractory mCRC

   This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   5 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT05319314 on ClinicalTrials.gov

10. A Study of MGC030 in Participants With Advanced Solid Tumors

    The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of MGC030. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors of select types. The main question the study aims to …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START New York-Long Island, Lake Success, New York

    Run by

    MacroGenics

    See if you can join NCT07822399 on ClinicalTrials.gov

11. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surg…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA ( Site 0317), Los Angeles, California

    Locations

    55 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06428409 on ClinicalTrials.gov

12. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA Santa Monica Hematology Oncology, Santa Monica, California

    Locations

    22 in total

    Run by

    Astellas Pharma Inc

    See if you can join NCT07094204 on ClinicalTrials.gov

13. SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

    This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or metastatic solid tumors. Phase 1 will identify the recommended dose t…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Full-Life Technologies Investigational Site, Minneapolis, Minnesota

    Locations

    2 in total

    Run by

    Full-Life Technologies UK Limited

    See if you can join NCT07873450 on ClinicalTrials.gov

14. BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours

    BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX ±…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cross Cancer Institue, Edmonton, Alberta

    Locations

    28 in total

    Run by

    Bold Therapeutics, Inc.

    See if you can join NCT04421820 on ClinicalTrials.gov

15. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 includes dose escalation cohorts evaluating PF-07220060 as sin…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Smilow Cancer Hospital - Yale New Haven Health, New Haven, Connecticut

    Locations

    39 in total

    Run by

    Pfizer

    See if you can join NCT04557449 on ClinicalTrials.gov

16. A Study of MGC026 in Participants With Advanced Solid Tumors

    The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    12 in total

    Run by

    MacroGenics

    See if you can join NCT06242470 on ClinicalTrials.gov

17. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a sui…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Oncology Institute of Hope and Innovation, Cerritos, California

    Locations

    104 in total

    Run by

    Boehringer Ingelheim

    See if you can join NCT06324357 on ClinicalTrials.gov

18. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

    Stage

    Phase 1

    Ages

    18 to 90

    Site

    VA Greater Los Angeles Healthcare System, Los Angeles, California

    Locations

    16 in total

    Run by

    Perspective Therapeutics

    See if you can join NCT06710756 on ClinicalTrials.gov

19. [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

    This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast can…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Locations

    2 in total

    Run by

    Blue Earth Diagnostics

    See if you can join NCT07432633 on ClinicalTrials.gov

20. Malignant Polyp Registry

    The purpose of this study is to learn more about malignant colorectal polyps (early colorectal cancers removed during colonoscopy) and the risk that cancer remains, comes back, or spreads after the polyp is removed. The researchers also want to understand how patients and doctors make decisions abo…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07619079 on ClinicalTrials.gov

21. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Banner Health, Gilbert, Arizona

    Locations

    16 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT04981119 on ClinicalTrials.gov

22. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    HonorHealth, Scottsdale, Arizona

    Locations

    30 in total

    Run by

    Verastem, Inc.

    See if you can join NCT07659795 on ClinicalTrials.gov

23. Collection of Information to Better Understand Young Onset Colorectal Cancer

    The purpose of this registry study is to create a database-a collection of information-for better understanding young onset colorectal cancer. Colorectal cancer patients are considered to have young onset colorectal cancer if they are diagnosed with their cancer before the age of 50. Researchers wi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

    Locations

    8 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04489238 on ClinicalTrials.gov

24. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Locations

    20 in total

    Run by

    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

25. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

    This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminar…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI at Florida Cancer Specialists, Orlando, Florida

    Locations

    6 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07807345 on ClinicalTrials.gov